Aprea Therapeutics (NASDAQ:APRE) vs. Affymax (OTCMKTS:AFFY) Financial Survey

Affymax (OTCMKTS:AFFY) and Aprea Therapeutics (NASDAQ:APRE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Profitability

This table compares Affymax and Aprea Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Affymax	N/A	N/A	N/A
Aprea Therapeutics	-2,666.46%	-88.12%	-68.78%

Institutional and Insider Ownership

34.2% of Aprea Therapeutics shares are owned by institutional investors. 1.6% of Affymax shares are owned by company insiders. Comparatively, 13.6% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Affymax and Aprea Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Affymax	N/A	N/A	N/A	N/A	N/A
Aprea Therapeutics	$1.50 million	4.57	-$12.96 million	($2.15)	-0.46

Affymax has higher earnings, but lower revenue than Aprea Therapeutics.

Analyst Ratings

This is a breakdown of recent recommendations for Affymax and Aprea Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Affymax	0	0	0	0	0.00
Aprea Therapeutics	1	0	2	0	2.33

Aprea Therapeutics has a consensus target price of $8.00, indicating a potential upside of 716.16%. Given Aprea Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Affymax.

Risk and Volatility

Affymax has a beta of 7.77, indicating that its share price is 677% more volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

Summary

Aprea Therapeutics beats Affymax on 6 of the 10 factors compared between the two stocks.

About Affymax

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

About Aprea Therapeutics

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.